Back to Search
MARIO LACOUTURE, MD
MD
Dermatology Physician
NPI: 1679563324IndividualAccepts Medicare
Specialties, Licenses & Credentials
Dermatology PhysicianPrimary
Dermatology
Code: 207N00000X
036113047(IL)254307(NY)
CMS Specialties
PrimaryDERMATOLOGY
Education
OTHER
Class of 2007
Research & Publications (20)
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
PMID 19213662·Clin Genitourin Cancer·2009
1-meta
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
PMID 19470276·J Natl Compr Canc Netw·2009
6-review
Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
PMID 19170238·Cancer·2009
8-other
Magnetic resonance imaging of paronychia induced by cetuximab.
PMID 19438534·Clin Exp Dermatol·2009
5-case
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.
PMID 19229368·Curr Oncol·2009
8-other
Analysis of dermatologic events in patients with cancer treated with lapatinib.
PMID 18600445·Breast Cancer Res Treat·2009
6-review
Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
PMID 19622903·Oncology·2009
1-meta
Dermatologic issues in adult survivors of childhood cancer.
PMID 19475513·J Cancer Surviv·2009
8-other
The growing importance of skin toxicity in EGFR inhibitor therapy.
PMID 19323302·Oncology (Williston Park)·2009
8-other
Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
PMID 19276294·Oncologist·2009
6-review
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
PMID 18550575·Ann Oncol·2008
8-other
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
PMID 18691458·J Natl Compr Canc Netw·2008
6-review
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
PMID 18779536·Oncologist·2008
6-review
An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.
PMID 18390464·Clin J Oncol Nurs·2008
6-review
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
PMID 18210295·Acta Oncol·2008
1-meta
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
PMID 18274784·Support Care Cancer·2008
6-review
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
PMID 18331788·Eur J Cancer·2008
8-other
Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials.
PMID 18794062·Clin Colorectal Cancer·2008
6-review
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
PMID 18160805·Oncology·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10065 - Phone
- (646) 888-6014
Quick Facts
- NPI
- 1679563324
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 19
- Publications
- 20
Are you this provider?
Claim Your Profile